ijms-logo

Journal Browser

Journal Browser

Molecular Research on Tumor Suppressor Proteins

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 July 2025 | Viewed by 839

Special Issue Editor


E-Mail Website
Guest Editor
Department of Microbiology and Molecular Genetics, University of California Davis, One Shields Ave., Davis, CA 95616, USA
Interests: DNA repair; homologous recombination; BRCA1/BRCA2; Rad51; Rad51 paralogs

Special Issue Information

Dear Colleagues,

DNA repair pathways are crucial for maintaining genome integrity and preventing tumorigenesis. Defective DNA repair factors can result in DNA abnormalities and irregular cell growth. Tumor suppressors such as BRCA1/BRCA2, PALB2, and RAD51C play essential roles in homologous recombination, a high-fidelity DNA repair pathway. This Special Issue aims to showcase recent research advances in the molecular mechanisms of tumor suppressor proteins in DNA repair pathways.

In this Special Issue of the International Journal of Molecular Sciences, we are calling for original research articles, reviews, and perspectives focusing on the molecular mechanisms underlying the essential functions of tumor suppressor proteins involved in DNA repair pathways. We are particularly interested in cellular, biochemical, and structural investigations of these DNA repair proteins, as well as contributions that focus on innovative research facilitating drug discovery and patient treatments.

We are seeking a diverse collection of high-quality original articles with in-depth analysis for this Special Issue. The focus is on enhancing our understanding of the intricate molecular strategies employed by DNA repair-related tumor suppressors to prevent genome abnormality and tumor formation. Your contributions to this Special Issue are welcome.

Dr. Jie Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • DNA repair
  • genome stability
  • tumor suppressor
  • BRCA1
  • BRCA2
  • PALB2
  • RAD51C

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2297 KiB  
Article
Plasma miR-145-5p Levels and Risk of Future Cancer—Results from the HUNT Study
by Christopher Antoun, Julia Oto, Vânia M. Morelli, Kristian Hveem, Sigrid K. Brækkan, Pilar Medina and John-Bjarne Hansen
Int. J. Mol. Sci. 2025, 26(5), 2191; https://doi.org/10.3390/ijms26052191 - 28 Feb 2025
Viewed by 520
Abstract
MicroRNA-145-5p (miR-145) has been reported to regulate multiple oncogenes and is considered a tumor suppressor. However, it remains unknown whether the level of plasma miR-145 can serve as a risk biomarker for future cancer. Using a population-based cohort (n = 1740) derived [...] Read more.
MicroRNA-145-5p (miR-145) has been reported to regulate multiple oncogenes and is considered a tumor suppressor. However, it remains unknown whether the level of plasma miR-145 can serve as a risk biomarker for future cancer. Using a population-based cohort (n = 1740) derived from the Trøndelag Health Study (HUNT), we investigated whether plasma miR-145 levels were associated with (1) first life-time cancer, (2) cancer stage at diagnosis, and (3) 2-year all-cause mortality after cancer diagnosis. Cox regression analysis was used to estimate hazard ratios (HR) and 95% confidence intervals (CI). Our findings showed that individuals in the highest quartile of plasma miR-145 levels had a 44% increased risk of developing cancer compared to those in the lowest quartile, independent of age, sex, body mass index, or smoking status (HR 1.44, 95% CI 1.03–2.00 p < 0.05). However, no association was observed between quartiles of miR-145 levels and the risk of being diagnosed with a metastatic cancer, or the risk of 2-year mortality after cancer diagnosis. Our findings suggest that high plasma miR-145 levels are associated with increased cancer risk without affecting the severity of the cancer at diagnosis or affecting the short-term prognosis. Full article
(This article belongs to the Special Issue Molecular Research on Tumor Suppressor Proteins)
Show Figures

Figure 1

Back to TopTop